Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
Zogenix, a biopharmaceutical company, announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on February 26, 2021, at 1:00 PM Eastern Time during the 10th Annual SVB Leerink Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zogenix, a biopharmaceutical company, announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on February 26, 2021, at 1:00 PM Eastern Time during the 10th Annual SVB Leerink Global Healthcare Conference. The event will be available via live webcast and archived on the company's Investor Relations site for 90 days. Zogenix focuses on developing therapies for rare diseases, including FINTEPLA, approved for Dravet syndrome, and other programs targeting rare genetic disorders.
Details
News Market Reaction – ZGNX
The recorded move for ZGNX in the trading session of this news was -1.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Friday, February 26, 2021, at the 10th Annual SVB Leerink Global Healthcare Conference.
| Zogenix Fireside Chat Details | |
| Date: | Friday, February 26, 2021 |
| Time: | 1:00 PM Eastern Time |
The fireside chat will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency (being developed through its subsidiary Modis Therapeutics). Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for genetic rare epilepsies.
CONTACTS:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.